60 cents..., page-5

A Dr Reddy's story

A snip

"The company?s profit, however, increased by about 32 per cent from Rs217.3 crore in the second quarter of last year to Rs286.7 crore.

?The US sales have started picking up in addition to a favourable product mix. We had to limited competition products giving us the results in the quarter. Growth in branded generics too an important factor among those contributing to the profitability,? Satish Reddy, COO and managing director of the company, said.

With the limited competition products beginning to play out, the company is expecting a strong second half during the financial year. The company last week launched generic Prevacid - lansoprazole - in the US market and is gearing up to go through the FDA inspection of its partners for generic Arixtra (fondaparnux)."


http://www.dnaindia.com/money/report_reddy-s-seeks-ally-to-bankroll-diabetes-drug-development_1457516